Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Alvotech faces challenges with potential tariffs and profitability, despite strong revenue growth and a robust pipeline. See ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

"Under the IRA, which discourages the research and development of additional indications for small molecule medicines ... and Johnson & Johnson's Stelara (ustekinumab). Calling the policy a ...

Andrew McConaghie reviews the findings of the latest pharma ranking index, which assesses on the premise: if you gave the same molecule to ... rheumatoid arthritis, Stelara for psoriasis and ...

Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for "Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0 mg." ...

A molecule named NM102 selectively inhibits the Mfd protein, a bacterial virulence and mutation factor, thereby disarming pathogenic bacteria without affecting beneficial microbiota.